The Effect of Adiponectin-Leptin Ratio on Weight Loss in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

The study aims to find out if a specific blood test, measuring the balance between two hormones (adiponectin and leptin), can predict how much weight a person might lose after sleeve gastrectomy, a surgery for obesity. The investigators want to see if this hormone ratio can help identify who will benefit most from the surgery. If the investigators find that people with a low hormone ratio are less likely to lose weight after surgery, doctors can guide them toward other weight-loss options, like lifestyle changes or different treatments, instead of surgery. This way, patients can get the care that's best for them.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Morbid Obesity Requiring Bariatric Surgery Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity, Morbid Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

About this study

The subject of the research is to investigate whether preoperative adiponectin-leptin ratios are predictive of weight loss in patients undergoing sleeve gastrectomy for morbid obesity. If the study finds the adiponectin-leptin ratio to be a significant predictor of weight loss, individuals with a low preoperative ratio, which are expected to lose less weight following surgery, can be redirected to more suitable treatment options other than sleeve gastrectomy. This will allow patients less likely to benefit from surgery to be guided toward conservative approaches.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 to 75
International Classification of Diseases (ICD) code E66 diagnosis (obesity)
Patients who have given consent for sleeve gastrectomy
Patients who are suitable for general anesthesia

Exclusion criteria

Patients who did not give consent to be included in the study
Patients who are scheduled for surgery other than sleeve gastrectomy

Treatment and study plan

Laparoscopic sleeve gastrectomy

Procedure

Laparoscopic Sleeve Gastrectomy

Primary outcomes

Change in body mass index at 8 months

Time frame: 8 months after surgery

Secondary outcomes

Change in lipid profile at 8 months

Time frame: 8 months after surgery

Sponsors and collaborators

Lead sponsor

Sercan YUKSEL, MD

Other Gov

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: May 4, 2026
Registry last updated: May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed